Spironolactone Tablet, Film Coated
Product Images NDC 71335-0053

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 71335-0053). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl713350053)

Label Image (Lbl713350053)
This is a description of a medication, Spironolactone, which is packaged and distributed by Bryant Ranch Prepack Burkbank. The medication is a yellow, round tablet with a strength of 25mg. Its active ingredient is not given. The packaging can be compared to Aldactone 25mg Tablet, instructions are given to store it at room temperature, and a warning is given to keep it out of children's reach. There is also information on the quantity - 30 tablets, and the expiration date, but it is not clear when it is set to expire. Finally, there is a National Drug Code (NDC) provided: NDC 7133500631 01830301523487.*
FDA Label Image

Figure 1. Survival By Treatment Group In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 1)

Figure 1.  Survival By Treatment Group In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 1)
The text provided is not-available as it lacks context and does not form a complete sentence or description. It appears to be only a fragment of statistical output obtained from a software program, and cannot be interpreted without additional information.*
FDA Label Image

Figure 2. Hazard Ratios Of All-cause Mortality By Subgroup In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 2)

Figure 2.  Hazard Ratios Of All-cause Mortality By Subgroup In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 2)
This appears to be a graph or table comparing the effectiveness of Spironolactone and a placebo drug, but without additional context it is difficult to provide a more detailed description.*
FDA Label Image

Chemical Structure (Spironolactone Structure Image)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.